Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus

MarketWatch2022-12-13

Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.

The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.

It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.

Shares fell 1.63% in premarket trade.

"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines," Chief Financial Officer Anat Ashkenazi said in a statement.

"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year." Eli Lilly also backed its guidance for 2022.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

pandajojo
2022-12-14
pandajojo
Like
- DMC8899:
  Ok
HH浩
2022-12-14
HH浩
Coffee maker?
Seah CL
2022-12-14
Seah CL
K
candyysk
2022-12-13
candyysk
Ok
- ChrisLiew:
  ok
来人
2022-12-13
来人
Ok
Aurum
2022-12-13
Aurum
Pls like and comment
- 来人:
  Done

Leave a comment

102

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153004318?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-12-13 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153004318","market":"us","top_or_hot":-1,"title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","media":"MarketWatch","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","article_id":"1153004318","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","pubTimestamp":1670932739,"columns":[],"sourceInfo":{"source_id":"lsy1603348471595","name":"MarketWatch"},"weMediaInfo":null,"summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"礼来公司为2023年设定指引，股价下跌，每股收益落后于当前共识","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":0.9},"content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":9921948738,"gmtCreate":1670972289124,"gmtModify":1676538467844,"author":{"id":"3578965435978206","authorId":"3578965435978206","name":"pandajojo","avatar":"https://static.tigerbbs.com/7efe44a2514d987c5a8b342b85d6f229","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3578965435978206","idStr":"3578965435978206"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9921948738","repostId":1153004318,"repostType":4,"repost":{"id":"1153004318","kind":"news","pubTimestamp":1670932739,"share":"https://ttm.financial/m/news/1153004318?lang=&edition=fundamental","pubTime":"2022-12-13 19:58","market":"us","language":"en","title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","media":"MarketWatch","summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153004318","content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105193893,"gmtCreate":1670979171861,"gmtModify":1670979184905,"authorId":3579992296424941,"author":{"id":3579992296424941,"idStr":"3579992296424941","authorId":3579992296424941,"name":"DMC8899","avatar":"https://community-static.tradeup.com/news/b7a615c27e1bfe97d99c855ee496cf6e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9921948738,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9921949045,"gmtCreate":1670971657787,"gmtModify":1676538467741,"author":{"id":"3582015516749888","authorId":"3582015516749888","name":"HH浩","avatar":"https://static.tigerbbs.com/2639351c97027c6f71c4d9729ef216d8","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3582015516749888","idStr":"3582015516749888"},"htmlText":"Coffee maker?&nbsp;","listText":"Coffee maker?&nbsp;","text":"Coffee maker?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921949045","repostId":1153004318,"repostType":4,"repost":{"id":"1153004318","kind":"news","pubTimestamp":1670932739,"share":"https://ttm.financial/m/news/1153004318?lang=&edition=fundamental","pubTime":"2022-12-13 19:58","market":"us","language":"en","title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","media":"MarketWatch","summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153004318","content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9921923634,"gmtCreate":1670967477428,"gmtModify":1676538467206,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4102135564535180","idStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921923634","repostId":1153004318,"repostType":4,"repost":{"id":"1153004318","kind":"news","pubTimestamp":1670932739,"share":"https://ttm.financial/m/news/1153004318?lang=&edition=fundamental","pubTime":"2022-12-13 19:58","market":"us","language":"en","title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","media":"MarketWatch","summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153004318","content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9921065477,"gmtCreate":1670941822700,"gmtModify":1676538463333,"author":{"id":"4097376940126320","authorId":"4097376940126320","name":"candyysk","avatar":"https://static.itradeup.com/news/64f60d94f5bea7832236facc0943ab72","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4097376940126320","idStr":"4097376940126320"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9921065477","repostId":1153004318,"repostType":4,"repost":{"id":"1153004318","kind":"news","pubTimestamp":1670932739,"share":"https://ttm.financial/m/news/1153004318?lang=&edition=fundamental","pubTime":"2022-12-13 19:58","market":"us","language":"en","title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","media":"MarketWatch","summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153004318","content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105191191,"gmtCreate":1670948949552,"gmtModify":1670948962188,"authorId":3580393689769738,"author":{"id":3580393689769738,"idStr":"3580393689769738","authorId":3580393689769738,"name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":11,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9921065477,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9921066456,"gmtCreate":1670941501075,"gmtModify":1676538463279,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3575544575320394","idStr":"3575544575320394"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921066456","repostId":1153004318,"repostType":4,"repost":{"id":"1153004318","kind":"news","pubTimestamp":1670932739,"share":"https://ttm.financial/m/news/1153004318?lang=&edition=fundamental","pubTime":"2022-12-13 19:58","market":"us","language":"en","title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","media":"MarketWatch","summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153004318","content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9921037186,"gmtCreate":1670936025445,"gmtModify":1676538462316,"author":{"id":"3581551558648648","authorId":"3581551558648648","name":"Aurum","avatar":"https://static.tigerbbs.com/9b62b380c4f32358425ddfcfada4c880","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581551558648648","idStr":"3581551558648648"},"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9921037186","repostId":1153004318,"repostType":4,"repost":{"id":"1153004318","kind":"news","pubTimestamp":1670932739,"share":"https://ttm.financial/m/news/1153004318?lang=&edition=fundamental","pubTime":"2022-12-13 19:58","market":"us","language":"en","title":"Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus","url":"https://stock-news.laohu8.com/highlight/detail?id=1153004318","media":"MarketWatch","summary":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a seri","content":"<html><head></head><body><p>Eli Lilly &amp; Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.</p><p>The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.</p><p>It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.</p><p>Shares fell 1.63% in premarket trade.</p><p><img src=\"https://static.tigerbbs.com/e3c957d4d8118e1de5210b73787a4430\" tg-width=\"866\" tg-height=\"836\" referrerpolicy=\"no-referrer\"/></p><p>&#34;We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,&#34; Chief Financial Officer Anat Ashkenazi said in a statement.</p><p>&#34;In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.&#34; Eli Lilly also backed its guidance for 2022.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...</p>\n\n<a href=\"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.marketwatch.com/story/eli-lilly-sets-guidance-for-2023-and-stock-falls-as-eps-lags-current-consensus-2022-12-13?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153004318","content_text":"Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide.The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30.It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion.Shares fell 1.63% in premarket trade.\"We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines,\" Chief Financial Officer Anat Ashkenazi said in a statement.\"In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year.\" Eli Lilly also backed its guidance for 2022.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105190139,"gmtCreate":1670941510635,"gmtModify":1670941523162,"authorId":3575544575320394,"author":{"id":3575544575320394,"idStr":"3575544575320394","authorId":3575544575320394,"name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9921037186,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":102,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153004318","isCrawlerRequest":true}